Riociguat for patients with chronic thromboembolic pulmonary hypertension: Usefulness of transitioning from phosphodiesterase type 5 inhibitor

Abstract Background Riociguat, the first approved drug for patients with chronic thromboembolic pulmonary hypertension (CTEPH), is a soluble guanylate cyclase (sGC) Stimulator. It directly stimulates sGC independently of nitric oxide (NO) and increases sGC sensitivity for NO. The safety and efficacy...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Respiratory investigation 2017-07, Vol.55 (4), p.270-275
Hauptverfasser:	Yamamoto, Keiko, MD, Tanabe, Nobuhiro, MD, PhD, FCCP, Suda, Rika, MD, PhD, Sasaki, Akane, MD, Matsumura, Akane, MD, Ema, Ryogo, MD, Kasai, Hajime, MD, PhD, Kato, Fumiaki, MD, PhD, Sekine, Ayumi, MD, PhD, Nishimura, Rintaro, MD, PhD, Jujo, Takayuki, MD, PhD, Sugiura, Toshihiko, MD, PhD, Shigeta, Ayako, MD, PhD, Sakao, Seiichiro, MD, PhD, Tatsumi, Koichiro, MD, PhD, FCCP
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Arterial Pressure Chronic Disease Chronic thromboembolic pulmonary hypertension Drug Substitution Female Humans Hypertension, Pulmonary - drug therapy Hypertension, Pulmonary - metabolism Hypertension, Pulmonary - physiopathology Internal Medicine Male Mean pulmonary arterial pressure Middle Aged Natriuretic Peptide, Brain - metabolism Oxygen Consumption Partial Pressure Phosphodiesterase 5 inhibitor Phosphodiesterase 5 Inhibitors - therapeutic use Pulmonary Artery - physiopathology Pulmonary Embolism - drug therapy Pulmonary Embolism - metabolism Pulmonary Embolism - physiopathology Pulmonary/Respiratory Pyrazoles - therapeutic use Pyrimidines - therapeutic use Soluble guanylate cyclase stimulator Time Factors Vascular Resistance Walk Test
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!